lisa_labSD said:They are two different exemptions from the same federal requirements and they buy different things.
Bookmarking. The distinction being drawn above is the one nobody else makes.
Adding the clinical framing, because it changes how the question reads.
Price comparison for compounded supply across sources I've used:
| Source | Monthly Cost | Type | Purity Verified |
|---|---|---|---|
| Brand (Ozempic) | $1039 | FDA-approved | N/A (pharma) |
| 503B Compounding | $169 | cGMP compounded | Yes (in-house) |
| 503A Compounding | $109 | Patient-specific | Varies |
| Research peptide | $54 | Not for human use | Often Janoshik |
I use the 503B option — best balance of quality, cost, and legality. The brand price is insane but insurance can help if you qualify.
Dr.NateNeph said:Compounding pharmacy response time test for compounded supply: I email customer service at odd hours to test responsiveness.
For compounded supply users considering compounded for the first time: here's a step-by-step guide:
Certified reference materials, analytical reagents, and research-grade standards for peptide verification. Trusted by laboratories worldwide.
Shop Reference StandardsTomTeleRx said:Resolution therefore closed the doors unevenly, and the asymmetry follows from the bulks lists.
Regarding compounded supply compounding legality: compounding pharmacies can legally produce semaglutide and tirzepatide while these drugs remain on the FDA shortage list. If/when the shortage resolves, the legal landscape may change.
Stay informed. The FDA shortage list is updated regularly. Current status as of my last check: semaglutide shortage ongoing, tirzepatide partially resolved. This directly impacts compounding availability.